INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following significant stock losses due to disappointing clinical trial results for its lead drug candidate, ersodetug [2][4]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [2]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [4]. Group 2: Clinical Trial Results - On December 11, 2025, Rezolute's shares experienced a sharp decline as the results from the Phase 3 sunRIZE clinical trial were released [4]. - The trial failed to meet both primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [4]. Group 3: Legal Implications - Investors who suffered significant losses in Rezolute stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1].